Oncopeptides AB Balances Growth, Cash Crunch in Earnings

Oncopeptides AB ((SE:ONCO)) has held its Q4 earnings call. Read on for the main highlights of the call.

Oncopeptides AB’s latest earnings call painted a cautiously optimistic picture, with strong revenue growth and scientific advances offset by ongoing losses and funding pressures. Management highlighted robust uptake of Pepaxti, exceptional margins and an emerging glioblastoma opportunity, but also warned of cash constraints, market headwinds and a delayed path to cash flow breakeven.

Strong Revenue Growth

Full‑year net sales jumped to SEK 71.1 million, a 125% increase versus the prior year, underscoring accelerating adoption of Pepaxti across Europe. Fourth‑quarter net sales reached SEK 18.6 million, up 88% year‑on‑year, though management acknowledged that Q3 and Q4 trends were softer than hoped in some key markets.

Very High Gross Margin

Gross profit for 2025 came in at SEK 68.7 million, translating into a striking 97% gross margin that underscores the inherent scalability of the product. This margin profile suggests that, if volume ramps as planned, incremental sales could materially improve profitability once fixed costs are better absorbed.

Improved Operating Efficiency

Cost discipline was a clear theme, with operating expenses down 16% in the quarter and 7% for the full year as the company tightened its spending profile. R&D fell roughly 15% to SEK 103 million and G&A was trimmed by about 5.6% to SEK 57.4 million, reflecting a more focused organization after prior restructuring.

Reduced Loss but Still Negative EBIT

EBIT improved meaningfully but remained deep in negative territory at minus SEK 224.7 million versus minus SEK 283 million a year earlier. The roughly SEK 58 million year‑on‑year reduction in losses shows progress on the path toward breakeven, yet underlines the scale still needed to cover commercial and development costs.

Capital Raise to Support Strategy

To fund its plan, Oncopeptides announced a rights issue of up to SEK 200 million, of which SEK 190 million is already backed by commitments and underwriting. Participation intentions from major shareholder HealthCap and from management and the board were highlighted as a signal of internal confidence in the long‑term strategy.

Commercial Momentum and Market Access

The company now has commercial organizations in Italy, Spain and Germany, forming the backbone of its European push. Italy has outperformed launch expectations, contributing to more than 600 patients treated since EMA approval and underpinning management’s estimate of a SEK 1.5 billion European market potential with exclusivity until 2037.

Promising Glioblastoma Pipeline Progress

On the R&D side, preclinical work in the GLIOPEP project showcased peptide‑drug conjugate OPD5 with near‑complete brain bioavailability in animal models and convincing tumor reduction. The dual mechanism of nuclear and mitochondrial DNA damage supports its potential in resistant tumors, with a small Phase 0 window study in glioblastoma planned for 2026.

Focused R&D and Externalization Strategy

Management stressed a leaner R&D model with no active clinical trials and a sharper focus on high‑value assets, particularly brain‑penetrant programs. Future development is expected to lean more on external partners and collaborations, allowing Oncopeptides to stretch capital while still advancing its preclinical platforms.

Need for Additional Capital and Cash Constraints

Year‑end cash stood at SEK 82 million, a level management described as insufficient to execute the strategy without fresh capital. The rights issue is therefore positioned as essential to bridge ongoing commercial investment and to finance the glioblastoma window study, signaling continued dependency on equity funding.

Delay to Cash Flow Positivity

The timeline to reach cash flow positivity has slipped by roughly a year, with the target now pushed from the end of 2026 into 2027. Management linked the delay to softer‑than‑expected Q3 and Q4 dynamics, including market disruptions and slower uptake, which require more time for the current cost structure to be absorbed.

Market Headwinds in Spain

Spain was a notable weak spot, as a prolonged medical doctor strike during the fourth quarter sharply reduced new patient starts and delayed treatment initiations. The company also cited an industry‑wide slowdown in late‑stage myeloma drugs in December, compounding the short‑term drag on Spanish sales momentum.

Slower‑Than‑Expected Growth in Germany

Germany delivered double‑digit growth but still lagged internal forecasts, reflecting structural challenges in the market. A fragmented prescriber base dominated by office‑based physicians with constrained pharma access, combined with rising competition, has lengthened the time needed to convert new doctors and ramp patient volumes.

Uncertain Commercial and Partnership Outlook Outside Europe

Beyond Europe, the picture remains murkier, with partnership discussions in Japan and other regions progressing slowly. Management flagged that timing is largely out of its control and that some regions face payer hurdles, meaning rest‑of‑world deals are unlikely to become a near‑term driver of revenue diversification.

Persistent Operating Loss and Valuation Impacts

Despite evident operational improvements, Oncopeptides remains solidly loss‑making, and full‑year financial items were further affected by a minus SEK 12.2 million non‑cash fair value adjustment on warrants. These factors keep pressure on the balance sheet and reinforce the importance of executing the rights issue and delivering top‑line growth.

High Commercial Spend and Concentrated Marketing

Sales and marketing spend stayed heavy at SEK 137.2 million, roughly unchanged year‑on‑year, reflecting the investment required to build a sustainable European franchise. With some key markets underperforming expectations, the company faces the challenge of extracting more revenue leverage from this sizable commercial cost base.

Reliance on Preclinical‑to‑Clinical Transition

At present there are no ongoing clinical trials, making the upcoming glioblastoma window study a critical inflection point for the pipeline. A successful demonstration of blood‑brain‑barrier passage in patients could unlock broader trials, but the scale of future development will depend heavily on both data quality and financing.

Forward‑Looking Guidance and Strategic Outlook

Management reaffirmed its plan to use proceeds from the up to SEK 200 million rights issue to fund European commercialization of Pepaxti and the planned Phase 0 glioblastoma study. The company is targeting positive cash flow in 2027, banking on continued high‑margin revenue growth, further cost discipline and selective investment into its brain‑penetrant oncology platform.

Oncopeptides’ call delivered a blend of encouraging commercial traction, stellar gross margins and intriguing glioblastoma data, counterbalanced by tangible financing and execution risks. Investors will be watching the rights issue uptake, progress in Germany and Spain, and early glioblastoma read‑outs closely to gauge whether the company can turn scientific promise into durable shareholder value.